Discovery & Selection of Novel Lymphatic-Targeted Prodrug Candidates to Treat Neuropsychiatric Disorders Using Clinical Evidence
Time: 1:30 pm
day: Day Two Track A - PM
Details:
- Selecting neuropsychiatric targets based on clinically validated mechanisms with existing limitations
- Using Seaport’s Glyph platform, a lymphatic-targeted prodrug technology to overcome these limitations, such as poor oral bioavailability or side effects of neuropsychiatric treatments and beyond.
- Sharing examples of the approach of identifying drugs with proven clinical efficacy and applying the Glyph platform to address previous challenges
